Earnings Call · Q1 FY2022·2022-05-11

Q1 22EPS -45.45%·Rev n/aQ4 21EPS +8.33%·Rev n/aQ3 21EPS -15.00%·Rev n/aQ2 21EPS -37.50%·Rev n/a⚠ consensus missing

PDS Biotechnology Corp PDSB

Gabrielle DeGravina — Investor Relations / Communications

Frank Bedu-Addo — Chief Executive Officer

Matthew Hill — Chief Financial Officer

−15.9%1d on move date−14.3% vs SPY3d+2.0%5d+19.7%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PDSB calls or request research access.

More PDSB calls Browse calls Request research access